Catapres ampoules ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
6Parkinson disease1

6. Parkinson disease


Clinical trials : 2,307 Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2007-004654-81-GB
(EUCTR)
20/12/200716/10/2007A phase IIa study to evaluate the relative efficacy and safety/tolerability of a single agent vs. a combination treatment for reducing saliva secretion in Parkinson’s disease patientsA phase IIa study to evaluate the relative efficacy and safety/tolerability of a single agent vs. a combination treatment for reducing saliva secretion in Parkinson’s disease patients Sialorrhoea associated with Parkinson's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10059812;Term: Sialorrhoea
Trade Name: Catapres ampoules
INN or Proposed INN: Clonidine hydrochloride
Trade Name: Ditropan elixir
INN or Proposed INN: Oxybutynin hydrochloride
Summit (Cambridge) Ltd.NULLNot RecruitingFemale: yes
Male: yes
Phase 2United Kingdom